Literature DB >> 10519736

Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing.

U E Busto1, L A Zawertailo, H L Kaplan, E M Sellers.   

Abstract

Drug abuse liability testing usually involves a subject population of individuals who are current or former drug abusers. To determine whether choosing subjects from a wider and more diverse population of nondrug abusers results in subjective response patterns that are pharmacologically associated with drug abuse liability, a series of studies were conducted using the prescription opiate hydromorphone and the barbiturate secobarbital to prescreen subjects before their acceptance into large multidrug, multidose abuse liability studies. The results of these prescreening studies show that there were some subjects who were not able to report consistently and reliably relevant drug effects, even though they received pharmacologically active doses as measured by objective indexes such as pupil diameter for the opiate study and psychomotor impairment for the barbiturate study. To test the consistency of these results, several of the subjects from the hydromorphone screening were retested with hydrocodone. The results demonstrate that subjects who were unable to report positive subjective effects of hydromorphone were also unable to respond appropriately to hydrocodone, and subjects who responded appropriately to hydromorphone in the prescreening study consistently responded to another opiate. Using this prescreening methodology has allowed sensitive and reliable data on the abuse liability of benzodiazepine agonists and partial agonists, barbiturates, carbamate compounds, amphetamines, selective serotonin reuptake inhibitors and prescription opiate compounds to be generated using a nondrug abusing population. In conclusion, due to the relative heterogeneity of a population of nondrug abusers compared with a drug abusing population, it is necessary to prescreen subjects for their ability to detect and report subjective drug effects, and to distinguish the effects of an active drug from those of placebo. Selecting subjects from this population has several advantages over selecting subjects from the drug abusing population that outweigh any inconvenience of this simple prescreening methodology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519736

Source DB:  PubMed          Journal:  Can J Clin Pharmacol        ISSN: 1198-581X


  3 in total

1.  Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial.

Authors:  Barth L Wilsey; Scott Fishman; Chin-Shang Li; Jeanna Storment; Anthony Albanese
Journal:  Pharmacol Biochem Behav       Date:  2009-08-04       Impact factor: 3.533

Review 2.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

3.  Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing.

Authors:  Denis G Antoine; Eric C Strain; D Andrew Tompkins; George E Bigelow
Journal:  Drug Alcohol Depend       Date:  2013-01-28       Impact factor: 4.492

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.